Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to acquire up to $700 million in BNB, following its recent all-time high price. The company is raising $520 million to support these purchases, on top of a previously announced $200 million plan. Partnering with crypto exchange Kraken for asset custody, Windtree will fund this initiative through a $500 million equity line of credit from an undisclosed institutional investor and an additional $20 million involving Build and Build Corp. CEO Jed Latkin emphasized that securing extra funds for BNB acquisition is crucial for the company's strategy. BNB, the fifth-largest cryptocurrency with a market cap of $106.9 billion, recently peaked at $808. Windtree joins a trend of public firms investing in cryptocurrencies, which has positively affected their stock prices, and follows the example of Strategy and other companies diversifying their crypto portfolios.

Source 🔗